In September 2023, Pitt professor José-Alain Sahel was contacted by a new federal agency looking to solve big problems.
What did Sahel think about the idea of a functional eye transplant — curing blindness by transplanting an eye from a donor into someone who had lost their sight. Was it feasible? Was it crazy?
Then — and now — Sahel doesn’t know.
“This is by definition a very ambitious goal,” said Sahel, distinguished professor and chairman of ophthalmology at the University of Pittsburgh. “We call that a moonshot. … Many of us shared that it was probably overambitious, but we would learn a lot along the way.”
More than a year later, the program has become a reality, with as much as $125 million in federal funding behind it. Pitt, Carnegie Mellon and Duquesne will all play a part in the six-year quest for a working eye transplant.
The project is part of a new, multibillion-dollar federal program, ARPA-H, dedicated to making scientific breakthroughs to transform medicine and health. The program is modeled after the Defense Advanced Research Projects Agency, or DARPA, the military innovation program created in the late 1950s that created the predecessor of the internet.
Read More
It is also modeled after Operation Warp Speed, the U.S. government’s public-private partnership created to accelerate the development of COVID-19 vaccines.
The program, formally called Transplantation of Human Eye Allografts, or THEA, was announced earlier this month. It encompasses four different teams of researchers working on different aspects of eye transplantation, with total funding of up to $125 million. Sahel is the co-lead of one of the teams — the team’s primary investigator is at Stanford University — which will receive up to $56 million. Pitt is in line to receive about $9 million.
“While there are therapies to slow the progression of vision loss, there are currently none that can bring back a person’s ability to see,” said ARPA-H THEA program manager Calvin Roberts, who initially contacted Sahel in 2023. “THEA and our performers intend to address this challenge, by transplanting the whole donor eye, reconnecting the nerves, muscles, and blood vessels to the brain and restoring vision. ARPA-H’s investments may eventually help generate new solutions for other neurological conditions, as well, such as spinal cord injuries.”
The first eye transplant was attempted at the end of the 19th century in France, said Sahel, noting that “it failed miserably.” Even as transplantation of other organs, such as the heart, liver and kidneys have become a reality, progress in functional eye transplantation has come slowly.
“It’s difficult for multiple reasons,” said Sahel, who is also the director of the UPMC Vision Institute. “The biggest challenge is the optic nerve. It’s like brain transplantation. There are 1.2 million fibers and you need to reconnect that properly.”
More than 70,000 people donate their eyes each year after death, and doctors are able to use the front surface of the eye and the cornea in transplants. But those transplants don’t help the many people who have lost their sight because of issues with their retinas or optic nerves.
Last year, a team at New York University performed the first eye transplant as part of a partial face transplant, though the eye is cosmetic, rather than functional.
The surgery at NYU was nonetheless a landmark for its ability to reconnect the eye post-transplant. Other recent scientific advances have paved the way for more discoveries about the optic nerve.

“The field of optic nerve regeneration has advanced considerably, demonstrating in pre-clinical models that various drugs and gene therapies can promote long distance regenerative growth,” said Jeffrey Goldberg, chair of ophthalmology at the Byers Eye Institute at Stanford University and the primary investigator for the team. “We are hopeful that applying these advances in the context of whole eye transplant can lead to meaningful steps forward.”
Some of those advances have come at Pitt, through the The Louis J. Fox Center for Vision Restoration of UPMC and the University of Pittsburgh, created in 2008 to pursue research in optic nerve regeneration.
The THEA program is divided into three technical areas to pursue functional eye transplant. The first is retrieval and maintenance of the donor eyes, keeping them viable for up to 48 hours before transplantation. The second area is optic nerve repair and regeneration and the third is actually implanting the eye into the recipient and reconnecting the blood vessels and nerves.
Pitt researchers will work on all three technical areas of the THEA program, while researchers from Duquesne will work on the first and third areas and Carnegie Mellon will work on the third technical area.
“We brought together all the talents around this question,” said Sahel. “This will generate a lot of good things for science.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.